KR20110047585A - Anti-obesity composition comprising Cordyceps militaris extracts - Google Patents
Anti-obesity composition comprising Cordyceps militaris extracts Download PDFInfo
- Publication number
- KR20110047585A KR20110047585A KR1020090104273A KR20090104273A KR20110047585A KR 20110047585 A KR20110047585 A KR 20110047585A KR 1020090104273 A KR1020090104273 A KR 1020090104273A KR 20090104273 A KR20090104273 A KR 20090104273A KR 20110047585 A KR20110047585 A KR 20110047585A
- Authority
- KR
- South Korea
- Prior art keywords
- fat
- extract
- diet
- obesity
- fat diet
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 230000003579 anti-obesity Effects 0.000 title claims abstract description 20
- 241001264174 Cordyceps militaris Species 0.000 title claims abstract description 9
- 235000013376 functional food Nutrition 0.000 claims abstract description 7
- 230000004580 weight loss Effects 0.000 claims abstract description 6
- 241001248610 Ophiocordyceps sinensis Species 0.000 claims description 31
- 241000190633 Cordyceps Species 0.000 claims description 21
- 239000000469 ethanolic extract Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 30
- 239000008280 blood Substances 0.000 abstract description 30
- 238000009825 accumulation Methods 0.000 abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 10
- 210000000577 adipose tissue Anatomy 0.000 abstract description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 4
- 239000012141 concentrate Substances 0.000 abstract description 3
- 239000002904 solvent Substances 0.000 abstract description 3
- 239000003960 organic solvent Substances 0.000 abstract description 2
- 238000001914 filtration Methods 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 235000009200 high fat diet Nutrition 0.000 description 53
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 17
- 235000021590 normal diet Nutrition 0.000 description 16
- 235000019786 weight gain Nutrition 0.000 description 13
- 238000010171 animal model Methods 0.000 description 12
- 235000005911 diet Nutrition 0.000 description 12
- 230000004584 weight gain Effects 0.000 description 11
- 208000008589 Obesity Diseases 0.000 description 10
- 235000020824 obesity Nutrition 0.000 description 10
- 230000037213 diet Effects 0.000 description 9
- 235000018823 dietary intake Nutrition 0.000 description 8
- 150000003626 triacylglycerols Chemical class 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000001596 intra-abdominal fat Anatomy 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 201000010063 epididymitis Diseases 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000382353 Pupa Species 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000007882 dietary composition Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000235349 Ascomycota Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241001480006 Clavicipitaceae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 241000805555 Podonectria Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000002844 continuous effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 235000021098 high calorie intake Nutrition 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 밀리타리스 동충하초(Cordyceps militaris) 추출물을 포함하는 항비만 조성물 및 그의 용도에 관한 것이다. The present invention relates to an anti-obesity composition comprising the extract of Cordillaps militaris and its use.
본 발명은 경기개발연구원의 경기도 전략기술개발사업의 일환으로 수행한 연구로부터 도출된 것이다.The present invention is derived from a study conducted as part of the Gyeonggi-do Strategic Technology Development Project.
[과제고유번호: A08081910, 과제명: 버섯, 버섯 균사체 및 포자를 활용한 항당뇨 기능성 소재 개발][Project number: A08081910, Title: Development of anti-diabetic functional material using mushrooms, mushroom mycelium and spores]
서구 선진국과 같이 우리나라에서도 최근 생활수준의 향상과 서구화된 식생활로 인해 비만 인구가 증가하고 있다. 1996년 WHO에서는 비만을 질병으로 규정하였고, 최근 경제협력개발기구(OECD)는 국가별 비만인구 비율이 20년 전에 비해 미국은 2배, 영국과 호주는 3배 가까이 증가되었다고 발표한 바 있다. 비만은 단순한 외형적 문제가 아니라, 고혈압, 고지혈증, 동맥경화, 심장질환, 제2형 당뇨병 등과 같은 성인병으로 이어지므로 심각한 건강 문제로 대두되고 있다.In Korea, as in western developed countries, obesity is on the rise due to the recent increase in living standards and westernized diet. In 1996, the WHO defined obesity as a disease, and the Organization for Economic Cooperation and Development (OECD) recently announced that the country's proportion of obese populations has doubled in the United States and nearly three times in the United Kingdom and Australia compared to 20 years ago. Obesity is not just a cosmetic problem, but is a serious health problem because it leads to adult diseases such as hypertension, hyperlipidemia, arteriosclerosis, heart disease,
체중과다 및 비만이 발생되는 이유는 섭취된 열량 중 소모되지 못하고 남은 열량이 지방으로 전환되어 체내의 여러 부분, 특히 피하조직과 복강내에 축적되기 때문이다. 이와 같은 지방 축적은 다양한 질병을 유발하는 원인이 된다. 지방축적으로 체중이 증가함에 따라 혈액 내의 콜레스테롤이나 중성지방 등의 성분들의 증가하여 고지혈증, 고콜레스테롤혈증 등의 발병률이 높아지며, 협심증, 심근 경색, 동맹경화 등과 같은 심혈관계 질환이 발생한다. 또한, 혈당을 조절하는 췌장에서 분비하는 인슐린이 지방으로 인해 인슐린 저항성을 갖게 되고 이로 인해 제 기능을 못해 당뇨병이 발병되기도 한다. Overweight and obesity occur because the amount of calories consumed and not consumed is converted to fat and accumulated in various parts of the body, especially the subcutaneous tissue and the abdominal cavity. Fat accumulation like this causes various diseases. As the body weight increases with fat accumulation, the incidence of hyperlipidemia and hypercholesterolemia increases due to the increase of cholesterol and triglycerides in the blood, and cardiovascular diseases such as angina pectoris, myocardial infarction and allergic hardening occur. In addition, insulin secreted by the pancreas, which controls blood sugar, has insulin resistance due to fat, which causes dysfunction, leading to diabetes.
비만 개선을 위해 개발된 대부분의 치료제들은 체중감량 및 유지에 효과가 있기는 했으나, 그 효과의 지속성에 의문이 있으며, 우울증, 불면증이나 소화장애 등과 같은 부작용을 유발하는 문제점을 갖는다. 따라서, 비만의 근본적인 원인을 치료하여 지속적인 비만 개선 효과를 가지며 부작용 및 독성 유발의 우려없이 안전하게 투여될 수 있는 비만 치료제에 대한 요구가 여전히 존재한다. Although most of the therapeutic agents developed to improve obesity are effective in weight loss and maintenance, there are questions about the sustainability of the effects, and problems such as depression, insomnia or digestive problems. Therefore, there is still a need for an anti-obesity agent that treats the underlying cause of obesity and has a continuous effect of improving obesity and can be safely administered without fear of side effects and toxicity.
이에, 본 발명자들은 우수한 비만 예방 및 경감 효과를 가지면서 체내에서 안전하게 작용하는 천연 물질에 대한 연구를 수행하여, 밀리타리스 동충하초(Cordyceps militaris) 추출물이 혈당을 저하시키며, 체지방 및 혈중 중성지방을 감소시키고, 혈중 HDL(high density lipoprotein)-콜레스테롤을 증가시켜 지방의 체내 축적을 억제하는 효과를 갖는다는 것을 발견하여 본 발명을 완성하였다.Therefore, the present inventors have conducted studies on natural substances that act safely in the body while having an excellent anti-obesity and alleviation effect, so that the extract of Cordyceps militaris lowers blood sugar, reduces body fat and blood triglycerides. The present invention was found to have an effect of inhibiting the accumulation of fat in the body by increasing blood HDL (high density lipoprotein) -cholesterol.
본 발명의 목적은 밀리타리스 동충하초 추출물을 포함하는 항비만 조성물을 제공하는 것이다. It is an object of the present invention to provide an anti-obesity composition comprising militaris cordyceps extract.
본 발명의 또 다른 목적은 밀리타리스 동충하초 추출물을 포함하는 항 비만 조성물을 포함하는 기능성 식품을 제공하는 것이다. Still another object of the present invention is to provide a functional food comprising an anti-obesity composition comprising the extract Militaris cordyceps.
상기 목적을 달성하기 위해, 본 발명은 밀리타리스 동충하초(Cordyceps militaris) 추출물을 포함하는 항비만 조성물을 제공한다. In order to achieve the above object, the present invention provides an anti-obesity composition comprising a extract of Millyris cordyceps (Cordyceps militaris).
식품의약안정청 식품원재료 데이터 베이스에 따르면, 동충하초는 겨울기간 동안 곤충의 체내에 서식하면서 양분을 흡수하여 숙주를 파괴시킨 후, 여름이 되면 곤충의 몸밖으로 식물체가 자라나는 모습에서 그 명칭이 유래되었다. 즉, 동충하초균의 포자 또는 균사가 곤충 또는 균핵에 침입하여 기주 안에 내생균핵을 만든 다음, 밖으로 자실체를 형성하는 것이 바로 동충하초버섯이다. According to the Food and Drug Administration's database of raw materials, Cordyceps sinensis inhabits insects during winter, absorbs nutrients, destroys the host, and grows out of insects in summer. In other words, the spores or mycelium of Cordyceps fungus invade insects or fungal nuclei to create endogenous fungal nuclei in the host, and then form fruiting bodies outside.
식물 분류체계상 동충하초는 자낭균강(Ascomycota), 맥각균 목(Clavicipitales), 맥각균과(Clavicipitaceae)에 속하며 코르디셉스(Cordyceps), 포도넥트리아(Podonectria), 토루비엘라(Torrubiella)의 세가지 속이 존재하고, 그 중 코르디셉스 속이 대표적이다(Kobayasi Y., Trans Mycol. Soc. Japan, 23. pp329-362, 1982). 코르디셉스 속에 속하는 밀리타리스 동충하초는 한국, 일본, 미국 등에 분포하며 번데기버섯이라고도 한다. 여름에서 가을에 걸쳐 잡목림의 땅속에 있는 곤충체에서 발생한다. 나비목 곤충의 번데기에 기생하며 자실체는 번데기 시체의 머리부분에서 발생하고 곤봉 모양이고, 자루는 둥근 기둥꼴이고 약간 구부러지며 등황색이나, 머리부분은 방추형으로 선명한 주황색이다. 피자기는 머리부분의 표피 속에 파묻혀 있고 그 속의 자낭 안에 가는 실 모양의 포자가 있고, 성숙하면 다시 갈라져서 2차 포자를 형성한다. According to the plant taxonomy, Cordyceps belongs to Ascomycota, Clavicipitales, Clavicipitaceae, and three genera of Cordyceps, Podonectria, and Torubiella. Among them, genus Cordyceps is representative (Kobayasi Y., Trans Mycol. Soc. Japan, 23. pp329-362, 1982). Militaris cordyceps, belonging to the genus Cordyceps, is distributed in Korea, Japan, and the United States and is also called pupa mushroom. Occurs in insect bodies in the land of mixed forests from summer to autumn. Parasitic on the pupa of lepidoptera insects. Fruiting bodies occur at the head of the chrysalis body, club-shaped, sack is round columnar, slightly curved, orange, but the head is fusiform and vivid orange. The pizzeria is embedded in the epidermis of the head, and there are thread-shaped spores in the inner scapula.
밀리타리스 동충하초는 항염증, 항균, 항종양, 면역증강 등 외부물질에 대한 보호작용, 노화방지, 질병 억제 및 완화 작용 등 다양한 효과를 갖는 것으로 알려져 있으나, 지방축적의 억제를 통한 비만 예방 또는 치료 효과에 관해서는 본 발명의 이전에 알려진 바 없었다. 본 발명자들은 밀리타리스 동충하초 추출물이 혈중 중성지방을 감소시키고 혈중 HDL-콜레스테롤을 증가시켜 지방축적을 저해한다는 것을 발견하였다. Militaris Cordyceps sinensis is known to have various effects such as anti-inflammatory, antibacterial, anti-tumor, and immune-enhancing effects such as protection, anti-aging, disease suppression and alleviation, but obesity prevention or treatment through inhibition of fat accumulation No effect was previously known of the present invention. The present inventors have found that the extract Millitaris cordyceps sinensis inhibits fat accumulation by decreasing blood triglycerides and increasing blood HDL-cholesterol.
본 발명의 일구체예에서, 상기 밀리타리스 동충하초 추출물은 물, 에탄올과 같은 친수성 유기용매 또는 이들의 혼합 용매에 의해 추출된 것일 수 있다. In one embodiment of the present invention, the Millitaris Cordyceps Sinensis extract may be extracted by water, a hydrophilic organic solvent such as ethanol, or a mixed solvent thereof.
본 발명의 일 구체예에서, 상기 밀리타리스 동충하초 추출물은 에탄올 추출물일 수 있다. In one embodiment of the present invention, the Millitaris Cordyceps Sinensis extract may be an ethanol extract.
본 발명의 일 구체예에서, 상기 밀리타리스 동충하초 추출물은 추출에 의해 수득되는 추출액, 추출액의 희석액 또는 농축액, 추출액을 건조하여 수득되는 건조물 또는 추출액의 조정제물 또는 정제물일 수 있다. In one embodiment of the present invention, the Millitaris Cordyceps Sinensis extract may be an extract obtained by extraction, a dilution or concentrate of the extract, a dried product obtained by drying the extract or a crude or purified product of the extract.
본 발명의 일 구체예에서, 밀리타리스 동충하초 추출물은 밀리타리스 동충하초 100g을 80% 에탄올 500ml과 혼합하는 단계, 상기 혼합물을 65℃에서 환류 냉각기를 부착하여 2시간씩 3회 추출한 후 여과지로 여과하는 단계, 상기에서 수득된 여액을 합하여 45℃에서 감압 농축하여 용매를 제거하는 단계, 및 상기 수득된 농축물을 동결건조하는 단계에 의해 제조하며 사용시까지 -70℃에서 보관할 수 있다.In one embodiment of the present invention, the millitaris Cordyceps sinensis extract is mixed with 500 ml of Millitaris Cordyceps Sinensis with 500 ml of 80% ethanol, and the mixture is extracted three times for 2 hours by attaching a reflux condenser at 65 ℃ and filtered through a filter paper It can be prepared by the step of, the combined filtrate obtained above and concentrated under reduced pressure at 45 ℃ to remove the solvent, and the step of lyophilizing the obtained concentrate and can be stored at -70 ℃ until use.
본 발명의 일 구체예에서, 상기 밀리타리스 동충하초 추출물은 조성물의 총 중량의 0.02 내지 90 중량%로 포함될 수 있다. 밀리타리스 동충하초 추출물이 조성물의 총 중량의 0.02 중량% 미만이면 항비만 효과가 검출가능하지 않은 수준이며, 90 중량%를 초과하는 경우에는 증가된 양에 비해 항비만 효과의 증가가 크지 않기 않다. In one embodiment of the present invention, the Millitaris Cordyceps Sinensis extract may be included as 0.02 to 90% by weight of the total weight of the composition. If the millitaris cordyceps sinensis extract is less than 0.02% by weight of the total weight of the composition, the anti-obesity effect is not detectable, and if it exceeds 90% by weight, the increase in anti-obesity effect is not large compared to the increased amount.
본 발명에 따른 항비만 조성물은 비만 예방 또는 치료용 약학적 조성물에 유효성분으로 포함될 수 있다. The anti-obesity composition according to the present invention may be included as an active ingredient in a pharmaceutical composition for preventing or treating obesity.
본 발명에 따른 항비만 조성물을 포함하는 약학적 조성물은 약학적 조성물의 제조에 통상적으로 사용되는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다. 본 발명의 일 구체예에 따른 약학적 조성물에 포함될 수 있는 약학적으로 허용가능한 담체, 부형제 및 희석제는 락토오스, 덱스트로오스, 수크로오스, 솔비톨, 만니톨, 자일리톨, 에리트리톨, 말티톨, 전분, 아카시아 고무, 알기네이트, 젤라틴, 칼 슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰오로스, 미정질 셀룰로오스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 마그네슘 스테라에리트 및 광물유를 포함하나, 이에 한정되지 않는다. Pharmaceutical compositions comprising an anti-obesity composition according to the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions. Pharmaceutically acceptable carriers, excipients and diluents that may be included in the pharmaceutical composition according to one embodiment of the invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, Alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and Including but not limited to mineral oils.
본 발명에 따른 약학적 조성물은 본 발명이 속하는 기술 분야에서 공지된 통상의 방법에 따라 정제, 캡슐, 과립제, 현탁액, 시럽 등의 다양한 제형으로 제형화되어 사용될 수 있다. The pharmaceutical composition according to the present invention can be formulated and used in various formulations such as tablets, capsules, granules, suspensions, syrups and the like according to conventional methods known in the art.
본 발명은 또한 밀리타리스 동충하초 추출물을 포함하는 조성물을 성분으로 포함하는 체중감량용 기능성 식품을 제공한다. The present invention also provides a functional food for weight loss comprising a composition comprising a Militaris Cordyceps Sinensis extract as a component.
본 발명에 따른 항 비만 조성물을 포함하는 체중감량용 기능성 식품은 어류, 육류, 음료, 초콜렛, 스낵류, 과자류, 라면, 기타 면류, 껌류, 아이스크림류, 비타민 복합체, 발효식품 등의 형태일 수 있다. Functional food for weight loss comprising the anti-obesity composition according to the present invention may be in the form of fish, meat, beverages, chocolate, snacks, confectionery, ramen, other noodles, gums, ice creams, vitamin complexes, fermented foods and the like.
본 명세서에서 사용되는 "기능성 식품"은 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미하며, "기능성"은 인체의 구조 및 기능에 대해 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다. As used herein, "functional food" means a food manufactured and processed using raw materials or ingredients having a useful function to the human body, and "functional" means nutrients or physiological effects on the structure and function of the human body. Ingestion means the purpose of obtaining a beneficial effect for the same health use.
본 발명의 일 구체예에서, 상기 항비만 조성물을 포함하는 체중감량용 기능성 식품은 식품 제조에서 허용가능한 통상적인 식품 첨가제, 예를 들면, 향미제, 풍미제, 착색제, 충진제, 안정화제 등을 더 포함할 수 있다. In one embodiment of the present invention, the functional food for weight loss comprising the anti-obesity composition further comprises conventional food additives, such as flavors, flavors, colorants, fillers, stabilizers, etc. that are acceptable in food production. It may include.
이하, 본 발명을 실험예에 의해 보다 상세하게 설명한다. 그러나 하기 실시예는 본 발명을 예시하기 위한 것에 불과하며, 본 발명의 범위를 한정하는 것으로 의도되지 않는다.Hereinafter, the present invention will be described in more detail with reference to experimental examples. However, the following examples are only intended to illustrate the invention and are not intended to limit the scope of the invention.
본 발명의 밀리타리스 동충하초 추출물을 포함하는 항비만 조성물은 체지방 및 혈중 중성지방을 감소시키고, 혈중 HDL-콜레스테롤을 증가시켜 지방 축적을 억제하고, 이에 의해 효과적으로 체중을 감량시켜 비만을 예방하고 치료할 수 있다. 본 발명의 조성물은 또한 혈당을 감소시키므로 당뇨병의 치료 또는 예방을 위해서도 이용할 수 있다. Anti-obesity composition comprising millilis cordyceps sinensis extract of the present invention can reduce body fat and blood triglycerides, increase blood HDL-cholesterol to inhibit fat accumulation, thereby effectively reducing weight to prevent and treat obesity have. The composition of the present invention can also be used for the treatment or prevention of diabetes because it reduces blood sugar.
실시예 1. 밀리타리스 동충하초 추출물의 제조 Example 1 Preparation of Millitaris Cordyceps Sinensis Extract
밀리타리스 동충하초를 100g 준비하고, 상기 약재를 80% 에탄올 500ml과 혼합하여 65℃에서 환류 냉각기를 부착하여 2시간씩 3회 추출 후 와트만(whatman) 2번 여과지로 여과하였다. 여액을 합하여 45℃에서 감압 농축하여 용매를 제거한 후 동결건조한 건조 추출물을 사용 전까지 -70℃에서 보관하였다. 100 g of Millitaris Cordyceps sinensis were prepared, and the medicinal herb was mixed with 500 ml of 80% ethanol, attached to a reflux condenser at 65 ° C., extracted three times for 2 hours, and then filtered through Whatman No. 2 filter paper. The combined filtrates were concentrated under reduced pressure at 45 ° C. to remove the solvent, and the lyophilized dry extract was stored at −70 ° C. until use.
실시예 2. 밀리타리스 동충하초 추출물에 의한 항비만 효과 Example 2 Anti-obesity Effect by Militaris Cordyceps Sinensis Extract
실시예 1에서 제조된 밀리타리스 동충하초 추출물의 항비만 효과를 확인하기 위해, 실험동물을 이용하여 체중증가량, 식이섭취량, 및 체지방무게를 측정하고 혈액 내 혈장을 분리하여 혈중콜레스테롤 및 혈중 중성지방 함량을 측정하였다. 사용된 실험동물은 ㈜ 대한 바이오링크로부터 구입한, 5주령의 체중이 17 내지 19 g인 C57BL/6 종 수컷 검은색 마우스였다. In order to confirm the anti-obesity effect of the extract of Millitaris cordyceps sinensis extract prepared in Example 1, the weight gain, dietary intake, and body fat weight were measured using experimental animals, and plasma was separated from blood to determine blood cholesterol and blood triglyceride content. Was measured. The experimental animals used were C57BL / 6 male black mice, weighing 17-19 g, 5 weeks of age, purchased from Daehan Biolink.
2-1. 체중증가 억제 2-1. Weight gain suppression
실시예 1에서 제조된 밀리타리스 동충하초 추출물의 체중증가에 대한 억제 효과를 확인하기 위해, 일정기간 동안 실험동물의 체중증가량과 식이섭취량을 측정하였다. 실험동물을 이용한 체중증가량과 식이섭취량 측정은 다음과 같이 수행하였다. 실험동물을 정상식이군과 고지방식이군의 두 군으로 나누었고, 각 군은 6 마리의 마우스로 구성되었다. 정상식이(#38057, Cargill Agri Purina Inc., Republic of Korea)는 총 열량의 4.5%를 지방으로 공급하였고, 고지방식이(#D12492, Research Diets Inc., United States of America)는 총 열량의 60%를 지방으로 공급하여 사육하였다. 정상식이준과 고지방식이군에 공급된 식이 조성은 하기 표 1에 표시된다. In order to confirm the inhibitory effect on the weight gain of the Militaris cordyceps sinensis extract prepared in Example 1, the weight gain and dietary intake of the experimental animals were measured for a certain period of time. Body weight gain and dietary intake were measured as follows. The experimental animals were divided into two groups, the normal diet and the high-fat diet, and each group consisted of 6 mice. The normal diet (# 38057, Cargill Agri Purina Inc., Republic of Korea) supplied 4.5% of total calories to fat, and the high-fat diet (# D12492, Research Diets Inc., United States of America) produced 60% of total calories. % Was fed as fat and raised. The dietary composition supplied to the normal diet and the high fat diet group is shown in Table 1 below.
표 1. 식이 조성Table 1. Dietary Composition
성분
ingredient
실험동물을 1주일 간 실험실 조건에 적응시킨 후에, 6주령부터 10주령까지 4주간 각각 정상식이(정상식이군), 고지방식이(고지방식이 대조군) 및 고지방식이와 밀리타리스 동충하초 추출물 0.05 중량%를 함유한 식이(고지방식이 실험군)를 공급하여 밀리타리스 동충하초 추출물에 의한 체중증가 억제 효과를 관찰하였다. 도 1 은 상기 조건의 식이 공급에 의한 체중 변화를 보여준다. After adapting the experimental animals to laboratory conditions for one week, the diet (normal diet group), high fat diet (high diet control), and high fat diet and Militaris cordyceps extract 0.05 weight each for 4 weeks from 6 to 10 weeks of age. Dietary supplements containing% (high-fat diet group) were fed to observe the effect of inhibiting weight gain by Militaris cordyceps extract. 1 shows the weight change by dietary feeding of these conditions.
실험동물은 각 군별로 세 마리씩 분리하여 사육하였고, 물과 식이는 제한 없이 공급하였다. 실험 기간 동안 식이 섭취량과 체중은 일주일에 2회 측정하였다. 식이효율 (Food Efficiency Ratio: FER)은 실험 식이 공급일로부터 희생일 까지를 총 실험기간으로 하여 실험 기간 동안의 체중 증가량을 실험 기간 동안의 식이 섭취량을 나누어 산출하였다. 그 결과를 하기 표 2에 각각의 실험군 별로 4 주간 체중 증가량과 식이 섭취량으로 표시하였다. Experimental animals were bred in three groups for each group, and water and diet were supplied without restriction. Dietary intake and body weight were measured twice a week during the experiment. The food efficiency ratio (FER) was calculated by dividing the amount of weight gain during the test period by dividing the dietary intake during the test period from the experimental diet supply date to the sacrifice day. The results are shown in Table 2 as weight gain and dietary intake for 4 weeks for each experimental group.
표 2. 밀리타리스 동충하초 추출물의 체중 증가에 대한 효과Table 2. Effect of Militaris Cordyceps Sinensis Extract on Weight Gain
정상식이
Normal diet
고지방식이
High-fat diet
*모든 데이터는 평균 ± 표준편차로 표시됨.* All data are displayed as mean ± standard deviation.
표 2에 표시된 바와 같이, 고지방식이에 밀리타리스 동충하초의 추출물을 중량 기준으로 0.05% 첨가한 식이를 섭취한 고지방식이 실험군의 경우, 고지방식이만을 섭취한 고지방식이 대조군에 비하여 체중증가가 약 6%가 감소하였다. 특히, 식이섭취량은 전기간 동안 고지방식이 실험군 및 고지방식이 대조군의 경우가 정상식이군보다 적었지만 고열량의 지방 섭취로 인하여 체중 증가량은 더 커서, 식이효율 (체중증가/식이섭취량*100)이 고지방식이군의 경우가 더 높았다. 그러나, 고지방식이와 함께 밀리타리스 동충하초 추출물을 0.05 중량% 투여한 고지방식이 실험군의 경우는 동일하게 고지방식이를 섭취하였음에도 불구하고 체중증가가 고지방식이 대조군보다 약 9% 낮은 것으로 분석되었다. As shown in Table 2, in the high-fat diet group in which the diet which added 0.05% of millitaris cordyceps extract to the high-fat diet was added to the diet, the high-fat diet only ingesting the high-fat diet increased weight compared to the control group. Decreased by about 6%. In particular, the dietary intake was lower in the high-fat diet group and the high-fat diet group than the normal diet group during the whole period, but the weight gain was greater due to the high calorie intake of fat, so that the dietary efficiency (weight gain / diet intake * 100) was higher. Lee group was higher. However, the high-fat diet with 0.05 wt% of Militaris cordyceps sinensis extract in combination with the high-fat diet was found to be about 9% lower than the high-fat diet, even though the high-fat diet was consumed. .
2-2. 체지방 축적 억제2-2. Inhibit body fat accumulation
실시예 1에서 제조된 밀리타리스 동충하초 추출물의 체지방 증가에 대한 억제 효과를 확인하기 위해, 실험동물의 체내 지방을 분리하여 그 중량을 측정하였다. In order to confirm the inhibitory effect on the increase of body fat of the Militaris cordyceps sinensis extract prepared in Example 1, the body fat of the experimental animal was separated and its weight was measured.
상기 2-1에 기재된 바와 같이 각각 정상식이, 고지방식이 및 고지방식이 + 밀리타리스 동충하초 추출물을 제공하여 사육된 실험동물을 10주령이 된 시기에 각 실험군에서 2마리 또는 3마리씩 희생시켜 혈액과 장기를 채취하였다. 적출한 장기에서 내장 지방(visceral fat), 신장 지방(peri-kidney fat) 및 부고환 지방(epididymal fat)을 각각 분리하여 그 중량을 측정하였다. 그 결과를 하기 표 3에 각각의 실험군의 부위별 지방 무게(100 g 체중당 지방 무게)를 표시하였다. As described in 2-1 above, the animals fed with normal diet, high fat diet and high fat diet + Militaris Cordyceps sinensis extract, respectively, were sacrificed by two or three animals in each experimental group at the time of 10 weeks of age. And organs were harvested. Visceral fat, kidney fat (peri-kidney fat) and epididymal fat were separated from the organs and their weights were measured. The results are shown in Table 3 below, the fat weight (fat weight per 100 g body weight) for each part of the experimental group.
표 3. 밀리타리스 동충하초 추출물의 체지방 중량에 대한 효과Table 3. Effect of Militaris Cordyceps Sinensis Extract on Body Fat Weight
*전체 지방은 내장 지방, 신장 지방 및 부고환 지방의 합을 의미한다.* Total fat is the sum of visceral fat, kidney fat and epididymal fat.
표 3은 고지방식이 섭취에 따른 체중 증가율의 차이가 체지방 축적량의 차이에서 기인된다는 것을 보여준다. 전체 지방 비율은 고지방식이군 대비 각 군의 전 체 지방(내장 지방, 신장 지방, 및 부고환 지방)의 중량의 합의 비율이다. 고지방식이와 밀리타리스 동충하초 추출물을 함께 섭취한 고지방식이 실험군의 경우, 고지방식이만을 섭취한 고지방식이 대조군에 비해 체지방 중량이 약 5% 감소했으며, 특히, 내장 지방의 경우는 정상식이군보다 지방 축적이 감소하였다. Table 3 shows that the difference in body weight gain with high fat diet is due to the difference in body fat accumulation. The percentage of total fat is the sum of the weights of the total fat (visceral fat, kidney fat, and epididymal fat) in each group relative to the high fat diet. In the high-fat diet group, which had high fat diet and Militaris cordyceps extract, the high-fat diet, which was fed only high-fat diet, reduced body fat weight by 5% compared to the control group, especially visceral fat group. Fat accumulation was reduced more.
2-3. 혈중 콜레스테롤 및 중성지방 축적 억제 2-3. Inhibition of blood cholesterol and triglyceride accumulation
실시예 1에서 제조된 밀리타리스 동충하초 추출물의 혈중 콜레스테롤 및 중성지방 함량에 대한 효과를 확인하기 위해, 실험동물의 혈액 내 콜레스테롤 및 중성지방의 양을 측정하였다. 실험동물을 이용한 혈중 콜레스테롤과 중성지방 함량 측정은 다음과 같이 수행하였다. In order to confirm the effect on the blood cholesterol and triglyceride content of the Militaris cordyceps sinensis extract prepared in Example 1, the amount of cholesterol and triglycerides in blood of the experimental animals was measured. Measurement of blood cholesterol and triglyceride content using experimental animals was performed as follows.
실시예 2-2에 기재된 바와 같이, 실험동물을 희생하기 직전에 안와정맥에서 채혈하여 채취한 혈액을 4000 rpm에서 10분간 원심분리하여 혈장을 수득하고 분석 시까지 -70℃에서 보관하였다. 혈장의 총 콜레스테롤, 중성 지방과 HDL-콜레스테롤은 아산제약에서 시판되는 키트(T-CHO, Cleantech TG-S, HDL-CHO, 아산제약, 한국)를 이용한 효소비색법으로 측정하였다. As described in Example 2-2, blood collected by orbital vein immediately before sacrifice of the experimental animal was centrifuged at 4000 rpm for 10 minutes to obtain plasma and stored at −70 ° C. until analysis. Plasma total cholesterol, triglycerides and HDL-cholesterol were measured by enzyme colorimetric method using a kit commercially available from Asan Pharmaceuticals (T-CHO, Cleantech TG-S, HDL-CHO, Asan Pharmaceutical, Korea).
표 4. 밀리타리스 동충하초 추출물의 혈중 콜레스테롤 및 중성지방 함량에 대한 효과Table 4. Effect of Militaris Cordyceps Sinensis Extract on Blood Cholesterol and Triglyceride Contents
표 4에 표시된 바와 같이, 혈중 총 콜레스테롤 함량은 고지방식이와 함께 밀리타리스 동충하초 추출물을 섭취한 고지방식이 실험군이 고지방식이만 섭취한 고지방식이 대조군에 비해 증가하였으나, 혈중 콜레스테롤의 함량을 낮춰주는 유용한 HDL-콜레스테롤은 고지방식이 실험군이 고지방식이 대조군보다 약 11% 증가한 것으로 관찰되었다. 혈중 중성지방은 고지방식이 대조군이 정상식이군에 비해 약 8% 증가한 반면, 밀리타리스 동충하초 추출물을 함께 섭취한 고지방식이 실험군은 훨씬 감소하여 고지방식이 대조군의 약 89% 수준으로, 정상식이군보다도 더 낮았다. As shown in Table 4, the total cholesterol content of blood was increased in the high-fat diet group, which was fed high-fat diet and Militaris cordyceps extract, but the high-fat diet was fed only high-fat diet, compared to the control group. Lowering useful HDL-cholesterol was observed in the high-fat diet group by about 11% more than the high-fat diet group. Serum triglycerides increased by about 8% in the high-fat diet control group compared to the normal diet group, while the high-fat diet group fed with Millitaris cordyceps extract was significantly reduced, which is about 89% higher than the normal diet group. Lower.
실시예 3. 밀리타리스 동충하초 추출물에 의한 항당뇨 효과 Example 3 Antidiabetic Effect by Militaris Cordyceps Sinensis Extract
실시예 1에서 제조된 밀리타리스 동충하초 추출물의 혈당강하 효과를 확인하기 위해, 실시예 2에 기재된 바와 같은 실험동물을 이용하여 혈액 내 혈장을 분리하여 혈당 함량을 측정하였다. 실험동물로부터 채혈 및 분리 후에 -70℃에서 보관한 혈장의 혈당을 아산제약에서 시판되는 키트(GLUCOSE, 아산제약, 한국)를 이용한 효소비색법으로 측정하였다. In order to confirm the hypoglycemic effect of the Millitaris cordyceps sinensis extract prepared in Example 1, the blood glucose content was measured by separating plasma from blood using an experimental animal as described in Example 2. Plasma blood glucose stored at −70 ° C. after blood collection and separation from experimental animals was measured by enzyme colorimetry using a kit commercially available from Asan Pharmaceuticals (GLUCOSE, Asan Pharmaceuticals, Korea).
표 5. 밀리타리스 동충하초 추출물의 혈당에 대한 효과Table 5. Effect of Militaris Cordyceps Sinensis Extract on Blood Sugar
표 5에 표시된 바와 같이, 고지방식이와 함께 밀리타리스 동충하초 추출물을 섭취한 고지방식이 실험군의 경우, 고지방식이만을 섭취한 고지방식이 대조군에 비해 혈당 감소를 보였다. 고지방식이에 의하여 혈당이 증가된 고지방식이 대조군은 정상식이군에 비하여 약 29%의 혈당이 증가한 반면, 밀리타리스 동충하초 추출물을 첨가한 고지방식이를 섭취한 고지방식이 실험군은 고지방식이 대조군보다 혈당이 약 10% 감소되었다. As shown in Table 5, in the high-fat diet experimental group ingested Militaris Cordyceps sinensis extract with the high-fat diet, high-fat diet only high-fat diet showed a decrease in blood glucose compared to the control group. The high-fat diet control group with increased blood sugar by the high-fat diet increased the blood sugar by about 29% compared to the normal diet group, while the high-fat diet group fed the high-fat diet with Militaris cordyceps extract added the high-fat diet control group. Blood sugar was reduced by about 10%.
도 1은 정상식이군(ND), 고지방식이 대조군(HFD), 및 고지방식이 실험군(HFD+CM(0.05%))의 시간의 경과에 따른 체중 변화량을 보여준다. Figure 1 shows the weight change over time of the normal diet group (ND), high-fat diet control group (HFD), and the high-fat diet group (HFD + CM (0.05%)).
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090104273A KR20110047585A (en) | 2009-10-30 | 2009-10-30 | Anti-obesity composition comprising Cordyceps militaris extracts |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090104273A KR20110047585A (en) | 2009-10-30 | 2009-10-30 | Anti-obesity composition comprising Cordyceps militaris extracts |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20110047585A true KR20110047585A (en) | 2011-05-09 |
Family
ID=44238872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090104273A KR20110047585A (en) | 2009-10-30 | 2009-10-30 | Anti-obesity composition comprising Cordyceps militaris extracts |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20110047585A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102641339A (en) * | 2012-04-25 | 2012-08-22 | 吉林大学珠海学院 | Chinese herbal medicine compound preparation for increasing body immunity and resisting fatigue |
WO2020241958A1 (en) * | 2019-05-28 | 2020-12-03 | 동아제약 주식회사 | Composition for preventing or treating woman menopause symptoms, comprising cordyceps militaris concentrate as active ingredient |
-
2009
- 2009-10-30 KR KR1020090104273A patent/KR20110047585A/en not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102641339A (en) * | 2012-04-25 | 2012-08-22 | 吉林大学珠海学院 | Chinese herbal medicine compound preparation for increasing body immunity and resisting fatigue |
WO2020241958A1 (en) * | 2019-05-28 | 2020-12-03 | 동아제약 주식회사 | Composition for preventing or treating woman menopause symptoms, comprising cordyceps militaris concentrate as active ingredient |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101613693B1 (en) | Composition for Prevention or Treatment of Skin Disease Comprising an Extract of Sargassum Horneri and Method of Preparing The Same | |
KR102110040B1 (en) | Composition for preventing and treating of obesity or metabolic disease comprising Elaeagnus umbellata extracts | |
KR101751398B1 (en) | Composition comprising Angelica gigas Nakai, Cornus officinalis, Cervi Parvum Cornu, Red ginseng, Rehmanniae Radix Preparata, Aquilaria agallocha Roxburgh and Honey for anti-inflammation | |
KR101464337B1 (en) | Composition for anti-obesity comprising extract of Diospyros lotus as effective component | |
KR20100122333A (en) | Compositions for the prevention and treatment of obesity, hyperlipidemia, atherosclerosis, fatty liver, diabetes mellitus or metabolic syndrome comprising extracts or fractions of glycine max leaves as an active ingredient | |
KR101484021B1 (en) | A Composition Comprising the extract of combined herbs including Curcuma Longa L. for immuno-stimulating activity | |
KR20170088314A (en) | Composition comprising Chrisanthemum indicum extract or fraction for treating, improving or preventing obesity or obesity-related disease | |
KR101729003B1 (en) | Composition For Preventing or Treating Gout Containing Extracts or Fermentation Metabolites of Dendropanax morbiferus | |
KR102002298B1 (en) | Compositions for preventing, ameliorating or treating hyperuricemia or metabolic disorders associated with hyperuricemia comprising herbal extracts | |
WO2016190566A9 (en) | Pharmaceutical composition or functional health food for preventing and treating metabolic diseases, containing water extract of pleurotus eryngii var. ferulae (pf.) as active ingredient | |
US20030161842A1 (en) | Pleurotus extract and use in treating hypertension | |
KR101497109B1 (en) | Composition for preventing, improving, or treating a disease controlled by PPAR action | |
KR20190035972A (en) | Composition comprising an extract of Elaeagnus umbellata for preventing and treating diabetes mellitus | |
KR20110047585A (en) | Anti-obesity composition comprising Cordyceps militaris extracts | |
KR101923603B1 (en) | A composition for anti-obesity comprising green tea complex extracts | |
KR101521341B1 (en) | Composition for prevention or treatment of anorexia comprising menispermum dauricum DC, menispermum dauricum DC extract, menispermum dauricum DC sludge or menisperum dauricum DC malt fermented liquid extract | |
KR20100064519A (en) | Composition comprising the extract of soybean leaves for the prevention, delay or treatment of gout | |
KR20140108104A (en) | Compositions comprising the combined extract of Artemisia iwayomogi and Curcuma longa for treating, inhibiting or preventing obesity-related disease | |
KR101618503B1 (en) | Novel endolichenic fungi and composition for preventing or treatment of gastric cancer or colorectal cancer comprising extracts thereof | |
KR101797993B1 (en) | Composition comprising crude drug of willow variant for treating, preventing or improvingcardiovascular disease | |
KR101001159B1 (en) | Composition for preventing or improving the diabete containing eriobotrya japonica extract | |
KR101824329B1 (en) | Composition comprising the fraction of Moutan Cortex Radicis extract for preventing or treating liver disases | |
KR20160059152A (en) | Anti-obesity composition comprising Cirsium japonicum leaf extract as effective component | |
KR101811210B1 (en) | Composition for treatment, improvement or prevention of Diabetes comprising extract of fruit of Sorbus commixta as an effective component | |
KR101904819B1 (en) | Composition comprising Fermented Momordica charantia L. and Allium sativum L. using Amyloliquefaciens Bacillus Jis-1 for lowering blood glucose or preventing and treating diabetes mellitus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |